At this point, the Food and Drug Administration could grant emergency-use authorization. In other words, the two vaccines could hinge on the combined results of 64 people. Haseltine concludes: If — or perhaps when — positive early results from these trials are announced, keep my warnings in mind. These protocols seem designed to get a… Read More: How COVID-19 drug/vaccine decisions might be based on little evidence »
Article content continued University of Regina psychology professor Dr. Gordon Asmundson: “The psychological footprint of the pandemic is likely as big, if not bigger, than the medical footprint.” Photo by Brandon Harder/Postmedia/File Psychotherapy, now more accessible than ever via virtual care, can help people cope with abnormal stressors, Frances says. What he doesn’t support is… Read More: More than 200 days in, COVID-19 is taking a psychological… »
Headlines about COVID-19 vaccine and drug trial pauses may ring alarm bells for millions of people watching their progress, but FDA Commissioner Stephen Hahn, M.D., has another point of view. The breaks in the action actually show the development process is working as intended, Hahn told Bloomberg. “The system was designed to identify safety issues,” he… Read More: No need to panic about COVID-19 trial halts, FDA chief… »
Loading the player… COVID-19 can do more than torment patients physically. It also clobbers some financially. Even though many insurers and the U.S. government have offered to pick up or waive costs tied to the virus, holes remain for big bills to slip through and surprise patients. People who weren’t able to get a test… Read More: COVID-19 coverage safety net has plenty of holes in US »